Novel approaches for detection and targeted therapy of prostate cancer using antibodies, aptamers, and nanobodies
Authors:
Open Access
- 17 October 2025
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 6 (23) , 8816-8838
Abstract
The graphical abstract illustrates a prostate cancer cell with antibodies (red), aptamers (green), and nanobodies (orange) binding to PSA/PSMA. Literature pages in the background show review synthesis, with diagnostic and therapy icons.Keywords
This publication has 170 references indexed in Scilit:
- Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancerClinical and Translational Medicine, 2022
- SELEX: Critical factors and optimization strategies for successful aptamer selectionBiotechnology and Applied Biochemistry, 2021
- Dual‐labeled prostate‐specific membrane antigen (PSMA)‐targeting agent for preoperative molecular imaging and fluorescence‐guided surgery for prostate cancerJournal of Labelled Compounds and Radiopharmaceuticals, 2020
- Secreted IgM: New tricks for an old moleculeJournal of Leukocyte Biology, 2019
- Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancerJournal of Cellular Biochemistry, 2019
- The Diagnosis and Treatment of Prostate CancerJAMA, 2017
- Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancerContrast Media & Molecular Imaging, 2014
- An Anti‐PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and TherapyAdvanced Healthcare Materials, 2012
- Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancerCancer, 2010
- Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate‐specific membrane antigen aptamers immobilized to a polymeric microfluidic deviceElectrophoresis, 2009